The Role of Protein Kinase C-alpha (PKC-) in Cancer and its Modulation by the Novel PKC--Specific Inhibitor Aprinocarsen

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|10|16|1923-1936

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.10, Iss.16, 2004-06, pp. : 1923-1936

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Pros and Cons of Targeting Protein Kinase c (PKC) in the Management of Cancer Patients

By  

Current Pharmaceutical Biotechnology, Vol. 12, Iss. 11, 2011-11 ,pp. : 1961-1973

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting Protein Kinase C (PKC) in Physiology and Cancer of the Gastric Cell System

By  

Current Medicinal Chemistry, Vol. 15, Iss. 12, 2008-05 ,pp. : 1175-1191

Bentham Science Publishers

Access to resources Recommend Favorite

Perspectives of Protein Kinase C (PKC) Inhibitors as Anti-Cancer Agents

By  

Mini Reviews in Medicinal Chemistry, Vol. 9, Iss. 4, 2009-04 ,pp. : 498-509

Bentham Science Publishers

Access to resources Recommend Favorite

Fine Tuning of Protein Kinase C (PKC) Isoforms in Cancer: Shortening the Distance from the Laboratory to the Bedside

By  

Mini Reviews in Medicinal Chemistry, Vol. 11, Iss. 3, 2011-03 ,pp. : 185-199

Bentham Science Publishers

Access to resources Recommend Favorite

A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-α administered as a 24-hour weekly infusion schedule in patients with advanced cancer

By Advani Ranjana   Lum Bert   Fisher George   Halsey Joanne   Geary Richard   Holmlund Jon   Kwoh T.   Dorr F.   Sikic Branimir  

Investigational New Drugs, Vol. 23, Iss. 5, 2005-10 ,pp. : 467-477

Springer Publishing Company

Access to resources Recommend Favorite